HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gordon, J. H. Articles by Diamond, B. I. Search for Related Content PubMed PubMed Citation Articles by Gordon, J. H. Articles by Diamond, B. I.

Estrogen in experimental tardive dyskinesia

Department of Pharmacology, University of Health Sciences/ the Chicago Medical School (Drs. Gordon, Borison, and Diamond), the Department of Anesthesiology, Mount Sinai Hospital (Drs. Borison and Diamond), and the Illinois State Psychiatric Institute (Dr. Borison) Chicago, IL.

Postmenopausal women have the highest incidence of tardive dyskinesia, suggesting that loss of ovarian function may predispose to this condition. Moreover, reports have indicated that estrogens could reduce abnormal movements in tardive dyskinesia. To test the effects of estrogen in tardive dyskinesia, ovariectomized rats were treated daily for 16 days with haloperidol alone (0.5 mg per kilogram) or haloperidol plus estradiol benzoate (EB; 8µg per kilogram). Rats were then challenged with apomorphine (0.25 mg per kilogram) 4 and 10 days after cessation of the chronic treatments. Chronic treatment with haloperidol alone enhanced the response to apomorphine, whereas the combined treatment produced a synergistic response. Rats treated chronically with haloperidol and then treated daily with EB after the haloperidol treatment showed an attenuation of drug-induced stereotypy. These data indicate that estrogen may mask development of tardive dyskinesia.

Address correspondence and reprint requests to Dr. Gordon, Department of Pharmacology, Chicago Medical School, 2020 West Ogden Avenue, Chicago, IL 60612.

This work was supported in part by USPHS Grant No. BSRGRR-5366, State of Illinois Department of Mental Health and Developmental Disabilities Grant No. 8009-1, and the Anesthesiology Research Fund, Mount Sinai Hospital, Chicago, IL.

Presented at the thirty-first annual meeting of the American Academy of Neurology, Chicago, April 1979.

Accepted for publication August 10, 1979.

This article has been cited by other articles:

				D. V. Jeste and R. Jed Wyatt Therapeutic Strategies Against Tardive Dyskinesia: Two Decades of Experience Arch Gen Psychiatry, July 1, 1982; 39(7): 803 - 816. [Abstract] [PDF]

				J. M. Kane and J. M. Smith Tardive Dyskinesia: Prevalence and Risk Factors, 1959 to 1979 Arch Gen Psychiatry, April 1, 1982; 39(4): 473 - 481. [Abstract] [PDF]